Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
DCL International Marks 40 Years of Engineering Innovation
GlobeNewswire, Inc.
TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- DCL International Inc. (DCL), part of the DCL Technology Group and a global leader in advanced catalytic technologies, celebrates its 40th anniversary with the launch of a refreshed brand identity that...
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
GlobeNewswire, Inc.
FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule.
Fieldguide Reaches Agreement with CPA Canada to Embed Trusted Canadian Engagement Forms within Industry-Leading Agentic AI
GlobeNewswire, Inc.
SAN FRANCISCO and TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Fieldguide, the leading transformation partner for agentic audit and advisory, today announced a new agreement with CPA Canada to embed the organization's trusted Professional...
Milestone Scientific Highlights Building a Scalable Growth Platform for CompuFlo® Medical Business
GlobeNewswire, Inc.
ROSELAND, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a medical technology company specializing in advanced computerized injection and drug-delivery technologies, today highlighted continued progress...
CEA Industries Inc. to Become BNB Standard Corporation After Open Community Advisory Vote
GlobeNewswire, Inc.
Nearly 6,000 advisory votes cast on four shortlisted names Common stock continues to trade on Nasdaq under “BNC” LOUISVILLE, CO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq: BNC) (“CEA Industries,” “BNC,” or the “Company”), a...
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
GlobeNewswire, Inc.
Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refractory acute myeloid leukemia Full Part A population expected to provide important efficacy insights across subjects who...
GATC Health's Derisq Named One of The Scientist's 2026 Top Innovations
GlobeNewswire, Inc.
GATC’s Derisq™, the definitive AI report for predictive risk intelligence, named a Top Emerging Startup Technology by independent panel of life sciences experts at the esteemed publication.
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
GlobeNewswire, Inc.
TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the...
MCPU Polymer Engineering Introduces 'Biocongruent Chemistry,' a New Framework for Sustainable Polymers, at Polycon 2026
EIN Presswire
Soy- and lignin-based additives replace halogenated flame retardant TCPP in polyurethane insulation foam and improve end-of-life biodegradation.
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
GlobeNewswire, Inc.
CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today...
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
GlobeNewswire, Inc.
PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today...
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
GlobeNewswire, Inc.
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with...
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
GlobeNewswire, Inc.
Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for...
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
GlobeNewswire, Inc.
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first quarter of 2028...
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
GlobeNewswire, Inc.
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from more than 1,100 U.S. MG patients indicates the...
Pam K. Crumpton, Featured By Influential Women, Connects Education And Training And Development In Industry
EIN Presswire
MOULTON, AL, UNITED STATES, September 29, 2026 /EINPresswire.com/ -- A Career Rooted in Learning, Community Engagement, and Helping Others Discover New Opportunities Moulton, Alabama – Pam K. Crumpton is an HR Training Specialist with YKTA...
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
GlobeNewswire, Inc.
OKYO demonstrates continued commitment to optometry and ophthalmology LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for...
Ocugen to Participate in Upcoming October Investor and Industry Conferences
GlobeNewswire, Inc.
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of its executive leadership...
Scintil Photonics Appoints Alexandru Romanescu as Vice President of Process Engineering
GlobeNewswire, Inc.
GRENOBLE, France, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Scintil Photonics, the global technology leader in Heterogeneous Integrated Photonics for next-generation DWDM AI infrastructure, today announced that Alexandru Romanescu has joined the company...
Kither Biotech Initiates Dosing of Patients in Phase 1b / 2a Study of KIT2014 in COPD
GlobeNewswire, Inc.
KIT2014 is a novel inhaled peptide therapy being developed for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF) The first...
Sign up for:
Technology News Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.